These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 4038776)

  • 1. Desferrioxamine and Alzheimer's dementia.
    King RG
    Med J Aust; 1985 Mar; 142(6):352. PubMed ID: 4038776
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine for Alzheimer's disease.
    Lancet; 1991 Aug; 338(8762):324-6. PubMed ID: 1677151
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular desferrioxamine in patients with Alzheimer's disease.
    Crapper McLachlan DR; Dalton AJ; Kruck TP; Bell MY; Smith WL; Kalow W; Andrews DF
    Lancet; 1991 Jun; 337(8753):1304-8. PubMed ID: 1674295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?
    Savory J; Exley C; Forbes WF; Huang Y; Joshi JG; Kruck T; McLachlan DR; Wakayama I
    J Toxicol Environ Health; 1996 Aug; 48(6):615-35. PubMed ID: 8772802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: ion specific chelation.
    Kruck TP; McLachlan DR
    Prog Clin Biol Res; 1989; 317():1155-67. PubMed ID: 2690090
    [No Abstract]   [Full Text] [Related]  

  • 7. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.
    Percy ME; Kruck TP; Pogue AI; Lukiw WJ
    J Inorg Biochem; 2011 Nov; 105(11):1505-12. PubMed ID: 22099160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1990 Oct; 48(4):439-46. PubMed ID: 2225704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
    McLachlan DR; Smith WL; Kruck TP
    Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
    Fine JM; Forsberg AC; Stroebel BM; Faltesek KA; Verden DR; Hamel KA; Raney EB; Crow JM; Haase LR; Knutzen KE; Kaczmarczek KD; Frey WH; Hanson LR
    J Neurol Sci; 2017 Sep; 380():164-171. PubMed ID: 28870559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron and aluminum in Alzheimer's disease.
    Di Lorenzo F; Di Lorenzo B
    Neuro Endocrinol Lett; 2013; 34(6):504-7. PubMed ID: 24378455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation.
    Anand A; Banik A; Thakur K; Masters CL
    Curr Alzheimer Res; 2012 Nov; 9(9):1010-29. PubMed ID: 22698073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
    Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation.
    Declercq SS
    Br J Ophthalmol; 1980 Aug; 64(8):626-9. PubMed ID: 7426580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial reversal of aluminium-induced neurofibrillary degeneration by desferrioxamine in adult male rabbits.
    Savory J; Herman MM; Erasmus RT; Boyd JC; Wills MR
    Neuropathol Appl Neurobiol; 1994 Feb; 20(1):31-7. PubMed ID: 8208339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.
    Fine JM; Renner DB; Forsberg AC; Cameron RA; Galick BT; Le C; Conway PM; Stroebel BM; Frey WH; Hanson LR
    Neurosci Lett; 2015 Jan; 584():362-7. PubMed ID: 25445365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aluminum and neurodegenerative disease: therapeutic implications.
    McLachlan DR; Kruck TP; VanBerkum MF
    Am J Kidney Dis; 1985 Nov; 6(5):322-9. PubMed ID: 2865894
    [No Abstract]   [Full Text] [Related]  

  • 19. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
    Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
    J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine B in ophthalmology. Applications and therapeutic possibilities.
    Valvo A
    Am J Ophthalmol; 1967 Jan; 63(1):98-103. PubMed ID: 6017683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.